On 2017 Dec 26, Evgeniy Gorbunov commented:

Subetta is not homeopathic drug. We have already answered to E.V. Dueva to the similar comment regarding another drug produced using the same biotechnological platform (please see here: https://www.ncbi.nlm.nih.gov/pubmed/28036118).

There are two references in Materials and Methods sections regarding Subetta manufacturing: to United States patent US8535664 (ref. 8), which E.V. Dueva mentioned in her comment; to the previously published work, where the drug preparation is briefly described (ref. 6).

The study was performed blindly by independent laboratory using validated experimental approach. The article is fully transparent for the readers so they have an opportunity to familiarize themselves with these results and make their own opinion.

The article passed peer-review process in accordance with the journal requirements. During the peer-review process, all necessary information had been provided including the images of blots.

On 2017 Dec 09, Evgenia V Dueva commented:

Subetta is made from antibodies diluted beyond Avogadro’s limit (12 consecutive dilutions of 1:100, see Google patents US8535664) and thus contains no active molecules. The authors do not mention homeopathy in their article, but this clearly is a homeopathic drug.

The results obtained by the authors are likely false positives considering the very low prior probability of a drug with no active molecules having any specific effect on insulin or any other receptors.

The authors did not provide any images of their blots, or information on the protein concentrations that they used. Without this critical information, it is unclear how the article passed peer-review.

On 2017 Dec 09, Evgenia V Dueva commented:

Subetta is made from antibodies diluted beyond Avogadro’s limit (12 consecutive dilutions of 1:100, see Google patents US8535664) and thus contains no active molecules. The authors do not mention homeopathy in their article, but this clearly is a homeopathic drug.

The results obtained by the authors are likely false positives considering the very low prior probability of a drug with no active molecules having any specific effect on insulin or any other receptors.

The authors did not provide any images of their blots, or information on the protein concentrations that they used. Without this critical information, it is unclear how the article passed peer-review.

On 2017 Dec 26, Evgeniy Gorbunov commented:

Subetta is not homeopathic drug. We have already answered to E.V. Dueva to the similar comment regarding another drug produced using the same biotechnological platform (please see here: https://www.ncbi.nlm.nih.gov/pubmed/28036118).

There are two references in Materials and Methods sections regarding Subetta manufacturing: to United States patent US8535664 (ref. 8), which E.V. Dueva mentioned in her comment; to the previously published work, where the drug preparation is briefly described (ref. 6).

The study was performed blindly by independent laboratory using validated experimental approach. The article is fully transparent for the readers so they have an opportunity to familiarize themselves with these results and make their own opinion.

The article passed peer-review process in accordance with the journal requirements. During the peer-review process, all necessary information had been provided including the images of blots.